BioCentury | Jun 10, 2020
Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

Autobahn, which launched with a $76 million series B Tuesday, joins at least six other companies with disclosed remyelination programs for multiple sclerosis. But the biotech thinks its prodrug, slated to enter the clinic next...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BioCentury | Jun 8, 2017
Translation in Brief

Barrier gateways

With induced pluripotent stem (iPS) cells making inroads into more and more areas of biology, two groups have now used the technology to generate models of the blood-brain barrier and pinpoint new molecular mechanisms contributing...
BioCentury | Jun 7, 2017
Distillery Techniques

Disease models

TECHNOLOGY: Cell models iPS cell-derived brain microvascular endothelial cells could serve as BBB models for HD or Allan-Herndon-Dudley syndrome. The cells were generated by co-culturing iPS cells derived from patients in endothelial cell-conditioned media with...
BioCentury | Apr 11, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on five genomic loci could help predict the risk of glioblastoma multiforme (GBM) and SNPs on eight genomic loci could help predict the risk of non-GBM glioma. Genome-wide association studies in 12,496...
BioCentury | Feb 11, 2013
Emerging Company Profile

GeneCentric: Cancer sign-off

...signature, also licensed from UNC, includes VEGF, angiopoietin-like 4 (ANGPTL4) , adrenomedullin (ADM; AM) and solute carrier family 16 member 3 (SLC16A3)...
BioCentury | Jul 28, 2011
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Stroke Monocarboxylic acid transporter 2 (SLC16A7; MCT2) Studies in mice suggest agonizing MCT2 could help treat sleep apnea-induced stroke. In a mouse model of sleep...
BioCentury | Dec 18, 2008
Targets & Mechanisms

Cancer's fuel duel

A team of Belgian and U.S. researchers has demonstrated that hypoxic tumor cells can be killed by targeting solute carrier family 16, member 1 (monocarboxylic acid transporter 1), a membrane lactate transporter protein expressed on...
BioCentury | Dec 11, 2008
Distillery Therapeutics

This week in therapeutics

The Distillery: Therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Solute carrier family 16, member 1 (monocarboxylic acid transporter 1) (SLC16A1; MCT1) Cell culture and mouse studies suggest that inhibiting MCT1...
Items per page:
1 - 9 of 9